Coloplast reported mixed Q4 20 numbers – missing revenue estimates and beating on profits. Sales were up 2% to DKK4.6bn – driven by ostomy and continence – while the EBIT margin was unchanged at 32%. The board proposed a final dividend of DKK13/share. For FY21, management expects top-line growth of 7-8% and an EBIT margin of 31-32%, largely in line with estimates. Following the largely expected performance, we do not expect any significant changes in our estimates/recommendation.
05 Nov 2020
Q4 20: Urology recovery surprises
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Q4 20: Urology recovery surprises
Coloplast A/S Class B (COLO.B:CSE), 0 | Coloplast A/S Class B (0QBO:LON), 0 | Coloplast A/S Class B (COLO:WBO), 0 | Coloplast A/S Class B (CBHD:ETR), 0 | Coloplast A/S Class B (CLPBF:OTC), 0 | Coloplast A/S Class B (CBHD:BRN), 0 | Coloplast A/S Class B (0QBON:MEX), 0
- Published:
05 Nov 2020 -
Author:
Virendra Chauhan -
Pages:
3
Coloplast reported mixed Q4 20 numbers – missing revenue estimates and beating on profits. Sales were up 2% to DKK4.6bn – driven by ostomy and continence – while the EBIT margin was unchanged at 32%. The board proposed a final dividend of DKK13/share. For FY21, management expects top-line growth of 7-8% and an EBIT margin of 31-32%, largely in line with estimates. Following the largely expected performance, we do not expect any significant changes in our estimates/recommendation.